Douros A - Search Results

1

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Dimakos J, Cui Y, Platt RW, Renoux C, Filion KB, Douros A. Dimakos J, et al. Among authors: douros a. Diabetes Care. 2023 Feb 1;46(2):377-383. doi: 10.2337/dc22-1584. Diabetes Care. 2023. PMID: 36525638

2

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.

Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Douros A, et al. Diabetes Care. 2017 Nov;40(11):1506-1513. doi: 10.2337/dc17-0595. Epub 2017 Sep 1. Diabetes Care. 2017. PMID: 28864502

3

Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study.

Douros A, Renoux C, Coulombe J, Suissa S. Douros A, et al. Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1546-1554. doi: 10.1002/pds.4333. Epub 2017 Oct 6. Pharmacoepidemiol Drug Saf. 2017. PMID: 28984052

4

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C. Douros A, et al. J Am Coll Cardiol. 2018 Mar 13;71(10):1105-1113. doi: 10.1016/j.jacc.2018.01.009. J Am Coll Cardiol. 2018. PMID: 29519351 Free article.

5

Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review.

Douros A, Ades M, Renoux C. Douros A, et al. CNS Drugs. 2018 Apr;32(4):321-334. doi: 10.1007/s40263-018-0507-7. CNS Drugs. 2018. PMID: 29536379

6

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.

Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Abrahami D, et al. Among authors: douros a. BMJ. 2018 Mar 21;360:k872. doi: 10.1136/bmj.k872. BMJ. 2018. PMID: 29563098 Free PMC article.

7

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Douros A, et al. BMJ. 2018 Jul 18;362:k2693. doi: 10.1136/bmj.k2693. BMJ. 2018. PMID: 30021781 Free PMC article.

8

Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.

Douros A, Abrahami D, Yin H, Yu OHY, Renoux C, Hudson M, Azoulay L. Douros A, et al. Epidemiology. 2018 Nov;29(6):904-912. doi: 10.1097/EDE.0000000000000891. Epidemiology. 2018. PMID: 30028343

9

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.

Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, Azoulay L. Douros A, et al. Diabetes Care. 2018 Nov;41(11):2330-2338. doi: 10.2337/dc17-2280. Epub 2018 Aug 27. Diabetes Care. 2018. PMID: 30150234

10

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L. Abrahami D, et al. Among authors: douros a. BMJ. 2018 Dec 5;363:k4880. doi: 10.1136/bmj.k4880. BMJ. 2018. PMID: 30518618 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters